PMV Pharmaceuticals, Inc.

What they do

PMV Pharmaceuticals is a precision oncology company founded in March 2013 that discovers and develops small molecule, tumor-agnostic therapies targeting the p53 tumor suppressor protein, whose mutations are found in approximately half of all cancers. Its lead candidate, rezatapopt, is an orally available small molecule designed to selectively correct p53 misfolding caused by the Y220C mutation while sparing wild-type p53. Rezatapopt is being evaluated in the Phase 1/2 PYNNACLE clinical trial in patients with advanced solid tumors harboring a TP53 Y220C mutation. The company has incurred losses in each year since inception, has no approved products for sale, and funds operations through capital raising.

Revenue drivers

• Rezatapopt (lead product candidate, pre-revenue) — No product sales to date; the company's only potential future revenue source is rezatapopt, an orally available small molecule targeting the p53 Y220C mutation, currently in a registrational Phase 2 monotherapy study in platinum-resistant/refractory ovarian cancer.
• Precision oncology platform pipeline (discovery/preclinical) — Described as a pipeline of orally available, potent and selective small molecule candidates targeting p53 mutations or other p53-related cancers; these programs are at the discovery and lead optimization stages and generate no revenue.

Recent performance

For the quarter ended June 30, 2026, PMV reported a net loss of $18.1 million, compared with $21.2 million for the quarter ended June 30, 2025, and a net loss of $36.1 million for the six months ended June 30, 2026. R&D expenses were $14.7 million for the second quarter of 2026 versus $18.4 million a year earlier, and G&A expenses were $4.2 million versus $4.5 million. Net cash used in operations was $34.3 million for the six months ended June 30, 2026, compared with $36.6 million for the prior-year period. The company ended the quarter with $79.4 million in cash, cash equivalents and marketable securities, down from $112.9 million at December 31, 2025, and reported an accumulated deficit of $482.6 million as of June 30, 2026. Full-year 2025 net loss was $77.7 million with operating cash use of $73.6 million, versus a 2024 net loss of $58.9 million.

Strategy

PMV's strategy is to pursue a tumor-agnostic development path for rezatapopt and seek regulatory approval under an accelerated pathway, with the Phase 2 portion of PYNNACLE intended to serve as a pivotal study. Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion has been completed, and the company plans to submit an initial NDA for accelerated approval in that indication in the first quarter of 2027. Rezatapopt holds FDA Fast Track designation for locally advanced or metastatic solid tumors with a p53 Y220C mutation and, as of March 2026, Orphan Drug Designation for TP53 Y220C positive ovarian, fallopian tube and primary peritoneal cancers. Management states it expects operating expenses to increase significantly as it advances development, seeks regulatory approval and prepares for potential commercialization. The company expects its existing cash to fund operations only into the second quarter of 2027 and states it will need to raise additional funding before any product revenue.

Risks

• Going-concern / funding need — PMV reported $79.4 million in cash, cash equivalents and marketable securities as of June 30, 2026 with expected runway only through the second quarter of 2027, and states it must raise additional funding before it can expect revenue from product sales.
• No approved product or revenue — The company has no product candidates approved for sale, has incurred losses in every year since inception, and had an accumulated deficit of $482.6 million as of June 30, 2026.
• Regulatory and clinical-trial risk — The planned first-quarter 2027 NDA for rezatapopt depends on the single-arm Phase 2 portion of PYNNACLE supporting accelerated approval, and any FDA failure to accept or grant that approval would delay or prevent the only near-term path to market.
• Dependence on a single product candidate — Rezatapopt targets the p53 Y220C mutation found in approximately 1% of all cancers (about 3% of ovarian cancers), and the rest of the pipeline remains at discovery and lead optimization stages, so the company's prospects are concentrated in that one program and a small patient population.

Outlook

Management plans to submit an initial NDA via accelerated approval for rezatapopt in platinum-resistant/refractory ovarian cancer with a TP53 Y220C mutation in the first quarter of 2027, following completed enrollment for the Phase 2 primary analysis. The company states it expects operating expenses to increase significantly as it advances product candidates, seeks regulatory approval and prepares for potential commercialization. It also states its existing cash, cash equivalents and marketable securities are expected to provide runway through the second quarter of 2027.